Cite
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.
MLA
Shi, Zhen-duo, et al. “Targeting HNRNPU to Overcome Cisplatin Resistance in Bladder Cancer.” Molecular Cancer, vol. 21, no. 1, Feb. 2022, pp. 1–16. EBSCOhost, https://doi.org/10.1186/s12943-022-01517-9.
APA
Shi, Z., Hao, L., Han, X., Wu, Z.-X., Pang, K., Dong, Y., Qin, J., Wang, G., Zhang, X., Xia, T., Liang, Q., Zhao, Y., Li, R., Zhang, S., Zhang, J., Chen, J., Wang, G., Chen, Z.-S., & Han, C. (2022). Targeting HNRNPU to overcome cisplatin resistance in bladder cancer. Molecular Cancer, 21(1), 1–16. https://doi.org/10.1186/s12943-022-01517-9
Chicago
Shi, Zhen-duo, Lin Hao, Xiao-xiao Han, Zhuo-Xun Wu, Kun Pang, Yang Dong, Jia-xin Qin, et al. 2022. “Targeting HNRNPU to Overcome Cisplatin Resistance in Bladder Cancer.” Molecular Cancer 21 (1): 1–16. doi:10.1186/s12943-022-01517-9.